A paper, made visible
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Abstract evidence6 comparisonsAutomated source matching · not expert reviewed
Quantitative results are not available to draw
- Available sources do not yet support a numeric visual.
What the available source describes
Study context is available. A quantitative result is not established here.
Study context 1 · source-backed descriptions
The numerical result is withheld from this picture. The estimate and interval could not be bound to one explicit statistical expression in the source.
What was examined
DPP-4 inhibitors
Inspect the source trail for this comparison
- Paper abstract ↗ · Results, paragraph 2abstract · Matched to source text; not expert scientific review
DPP-4 inhibitors were associated with lower risks for all-cause death (hazard ratio [HR], 0.63 [95% CI, 0.55 to 0.72]), MACEs (HR, 0.68 [CI, 0.55 to 0.83]), ischemic stroke (HR, 0.64 [CI, 0.51 to 0.81]), and hypoglycemia (HR, 0.43 [CI, 0.33 to 0.56]) compared with sulfonylureas as add-on therapy to metformin but had no effect on risks for myocardial infarction and hospitalization for heart failure.
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
DPP-4 inhibitors were associated with lower risks for all-cause death (hazard ratio [HR], 0.63 [95% CI, 0.55 to 0.72]), MACEs (HR, 0.68 [CI, 0.55 to 0.83]), ischemic stroke (HR, 0.64 [CI, 0.51 to 0.81]), and hypoglycemia (HR, 0.43 [CI, 0.33 to 0.56]) compared with sulfonylureas as add-on therapy to metformin but had no effect on risks for myocardial infarction and hospitalization for heart failure.
Study context 2 · source-backed descriptions
The numerical result is withheld from this picture. The extraction quotation could not be matched to the available source.
What was examined
DPP-4 inhibitors
sulfonylureas
Inspect the source trail for this comparison
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
However, large-scale studies of the effects on cardiovascular outcomes of adding DPP-4 inhibitors versus sulfonylureas to metformin therapy remain scarce.